Clinical Blogs

In this blog, we take a look at four areas that the workers' compensation industry forecasted emergent issues before they impacted general health care.

As the pharmaceutical industry continues to take on an expanding role in the development of breakthrough medication, pharmacy solutions organizations will be just as essential in ensuring their successful delivery.

One result of the pandemic that surprised many in our field last year was the limited impact of COVID-19 treatment on retail pharmacy spend.

myMatrixx has integrated e-prescribing and digital provider engagement technology into our workers’ compensation pharmacy program and it is an integral part of our online adjudication system.

As we continue to move into 2021, two of the biggest concerns in workers’ compensation pharmaceuticals remain the ongoing COVID-19 pandemic and the opioid misuse crisis.

On Wednesday April 14, myMatrixx Chief Clinical Officer, Phil Walls, was joined by Marcos Iglesias MD, Chief Medical Director of the Travelers and Constitution State Services to discuss the interaction between behavioral health and chronic pain management in workers’ compensation.

As the workers’ compensation industry moves into a new year, many of the major topics that will drive the field in 2021 are starting to come into focus.

In a new piece for Risk & Insurance, myMatrixx Chief Clinical Officer, Phil Walls, shares four major reasons why people in workers’ comp, and the larger health care industries, need to stay focused on opioid misuse.

As the workers’ comp and pharmaceuticals industries continue to make progress in the fight against opioid misuse, it’s important to remain vigilant around new pain treatments that are filling this vacuum.

On Wednesday, January 27th, myMatrixx Chief Clinical Officer, Phil Walls, will join the Hartford’s Chief Medical Officer, Adam L. Seidner, in a virtual session for the National Workers’ Compensation and Disability Conference (NWCDC).